PDS Biotechnology (NASDAQ:PDSB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of PDS Biotechnology (NASDAQ:PDSB) from a sell rating to a hold rating in a research report report published on Monday morning,Wall Street Zen reports.

A number of other research firms have also recently commented on PDSB. Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 28th. HC Wainwright reaffirmed a “buy” rating on shares of PDS Biotechnology in a report on Wednesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, PDS Biotechnology presently has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Price Performance

PDSB stock opened at $1.06 on Monday. The firm has a market cap of $59.61 million, a P/E ratio of -1.66 and a beta of 1.17. The company has a debt-to-equity ratio of 2.73, a quick ratio of 0.57 and a current ratio of 0.57. PDS Biotechnology has a 1 year low of $0.20 and a 1 year high of $1.55. The stock has a 50-day simple moving average of $0.52 and a 200-day simple moving average of $0.80.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). On average, equities analysts predict that PDS Biotechnology will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in PDS Biotechnology during the 2nd quarter valued at $535,000. Bank of New York Mellon Corp bought a new stake in shares of PDS Biotechnology in the 2nd quarter worth about $60,000. Finally, Renaissance Technologies LLC increased its position in shares of PDS Biotechnology by 25.0% in the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock worth $134,000 after purchasing an additional 44,100 shares during the last quarter. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer and infectious diseases. The company’s technology is designed to stimulate the immune system and generate antigen-specific T-cell responses against diseased cells.

PDS Biotech’s lead investigational product is PDS0101, an immunotherapy designed to target human papillomavirus type 16 (HPV16) antigens E6 and E7. The product is being evaluated in combination with other treatments for HPV16-associated cancers, including cervical, anal, and certain head and neck cancers.